Navigation Links
Warner Chilcott Announces 2011 Financial Guidance Conference Call
Date:1/27/2011

DUBLIN, Jan. 27, 2011 /PRNewswire/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that it will issue its 2011 financial guidance prior to the market opening on Tuesday, February 15, 2011.

In addition to issuing a press release, the Company will host a conference call for all interested parties on Tuesday, February 15, 2011 at 8:00 AM (Eastern Time) to review the guidance. To participate in the call, please dial (877) 354-4056 in the United States and Canada or (678) 809-1043 internationally.  

"The timing of our guidance call is a bit later than has been our past practice," commented CEO, Roger Boissonneault.  "This will allow us to gather additional data on the early January launches of two exciting new products for Warner Chilcott, ATELVIA, a next generation oral bisphosphonate, and LO LOESTRIN FE, a novel oral contraceptive."

Investors and other interested parties may also access the conference call via a simultaneous audio webcast by visiting http://ir.wcrx.com and clicking on Events & Presentations.  

A replay of the conference call will be available for two weeks following the call and can be accessed by dialing (800) 642-1687 within the United States and Canada or (706) 645-9291 internationally.  The passcode for the replay is 40140054.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-F


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
(Date:2/16/2017)... BEACH, Florida , February 16, 2017 /PRNewswire/ ... improving with the infusion of innovative telemedicine application, ... monitoring services that are experiencing a boom worldwide. ... with the advancement of technologies, services and new ... Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. ...
(Date:2/16/2017)... , Feb. 16, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, today ... 1a financing and entered into a $5 million ... intends to use the capital for general corporate ... advancements in the treatment of serious diseases treated ...
Breaking Biology Technology:
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):